The DEBATE Study "DEvelopment of Endotype-based Biomarkers for the Monitoring of Greek pATiEnts With CRSwNP"

Inclusion Criteria

• •Age ≥ 18 years
• •If CRSwNP group:
• •Physician-diagnosed severe, uncontrolled CRSwNP according to the EUFOREA/EPOS 2020 and ICAR-RS 2021 guidelines with:
• •CRSwNP severity consistent with the need for surgery as defined by a total nasal polyp score (NPS) of ≥5 (≥2 for each nostril)
• •Nasal Congestion Score (NCS) of ≥2
• •Ongoing documented symptoms of CRSwNP for \> 8 weeks before surgery
• •If CRSsNP group:
• •Diagnosis of CRSsNP according to the EUFOREA/EPOS 2020 and ICAR-RS 2021 guidelines
• •Have performed in the period between 2012 and enrolment or are scheduled to perform endoscopic sinus surgery (ESS) for the first time at enrolment
• •Have available nasal polyp tissue sample from the first endoscopic sinus surgery (ESS)
• •Have provided signed and dated written informed consent
• •If CRSwNP group:
• •Patients receiving any standard of care treatment for CRSwNP, provided the participant is stable on that treatment for ≥30 days